Wafer Fab Equipment, M&A Moves & The Lab 7 You've Never Heard Of

The episode begins with an overview of the current focus on the 'Fab 5'—ASML, Applied Materials, Lam Research, Tokyo Electron, and KLA Corp—and their dominant role in the wafer fab equipment industry, controlling about 70% of global spending. The discussion highlights why 2024 and the upcoming years are expected to have record revenues for these companies, with potential cyclical downturns around 2028. The host emphasizes the importance of understanding the cyclical nature of the semiconductor market and the strategic investments that can be made in this space, including diversification strategies such as dollar-cost averaging.

The episode explores recent and upcoming M&A activities reshaping the industry, including the merger of Axcelis and Veeco, which is awaiting approval from China, and Applied Material's acquisition of a segment from ASMPT, mainly for advanced packaging equipment. The discussion points out that companies often prefer to acquire smaller segments rather than entire competitors to avoid antitrust issues and to consolidate market share economically. This segment discusses how M&A activity indicates ongoing industry consolidation and the potential investment opportunities arising from these moves.

Attention is given to innovative companies like Onto Innovation and their strategic investments, such as their stake in Rigaku, which specializes in X-ray imaging—crucial for quality control in advanced semiconductor manufacturing. Onto's focus on metrology and software, along with their creative partnerships and acquisitions, indicates a resilient and evolving segment of the industry. Despite elevated valuations, these companies are seen as durable due to high recurring revenue streams and demand for their services, especially in advanced imaging and metrology.

The episode introduces 'Lab 7,' a group of life sciences and laboratory equipment providers including Thermo Fisher, Agilent, Brooker, and Revvity. These companies have structural overlaps with the semiconductor supply chain, mainly through their focus on lab capital equipment and consumables. The host discusses how the convergence between the healthcare/life sciences industry and semiconductors might develop, driven by overlapping tech and innovation. The segment emphasizes that these companies can serve as diversification options for investors concerned about overconcentration in the semiconductor sector, especially given recent volatility and M&A activity.